Literature DB >> 9552393

DNA damage checkpoints: implications for cancer therapy.

P M O'Connor1, S Fan.   

Abstract

DNA damage evokes a complex array of cellular responses, including cycle arrest in late G1 and/or G2 phases, and delayed progression through S phase. Arrest at these points in the cell cycle is governed, in large part, by a series of control systems, commonly termed "checkpoints". Activation of these checkpoints tends to protect cells from DNA damage by providing cells additional time to complete DNA repair. We discuss the impact of these DNA damage checkpoints on the chemosensitivity of human cancer cells. We focus on some of the complexities of the p53-dependent G1 checkpoint and review some recently discovered vulnerabilities in p53 disrupted cells that might be pharmacologically exploited for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9552393     DOI: 10.1007/978-1-4615-5873-6_16

Source DB:  PubMed          Journal:  Prog Cell Cycle Res        ISSN: 1087-2957


  10 in total

1.  Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells.

Authors:  Seema Gupta; Sabapathi Sathishkumar; Mansoor M Ahmed
Journal:  Pancreatology       Date:  2010-10-29       Impact factor: 3.996

Review 2.  Resistance and gain-of-resistance phenotypes in cancers harboring wild-type p53.

Authors:  Michelle Martinez-Rivera; Zahid H Siddik
Journal:  Biochem Pharmacol       Date:  2011-12-26       Impact factor: 5.858

3.  A herbal medicine for the treatment of lung cancer.

Authors:  Rama S Ranga; Srinivasan Sowmyalakshmi; Ravshan Burikhanov; Mohammed A Akbarsha; Damodaran Chendil
Journal:  Mol Cell Biochem       Date:  2005-12       Impact factor: 3.396

4.  Multiple defects of cell cycle checkpoints in U937-ASPI3K, an U937 cell mutant stably expressing anti-sense ATM gene cDNA.

Authors:  J Zhou; W Liu; L Sun; H Sun; Y Tang
Journal:  J Tongji Med Univ       Date:  2000

5.  Long-term smoking mediated down-regulation of Smad3 induces resistance to carboplatin in non-small cell lung cancer.

Authors:  Debangshu Samanta; Jacob Kaufman; David P Carbone; Pran K Datta
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

6.  Ligand modulation of a dinuclear platinum compound leads to mechanistic differences in cell cycle progression and arrest.

Authors:  Vijay R Menon; Erica J Peterson; Kristoffer Valerie; Nicholas P Farrell; Lawrence F Povirk
Journal:  Biochem Pharmacol       Date:  2013-10-24       Impact factor: 5.858

7.  Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin.

Authors:  Viktor Horváth; Karel Soucek; Lenka Svihálková-Sindlerová; Jan Vondrácek; Olga Blanárová; Jirina Hofmanová; Petr Sova; Alois Kozubík
Journal:  Invest New Drugs       Date:  2007-05-23       Impact factor: 3.850

8.  Failure to inactivate CDK activity is responsible for the enhanced apoptotic response in U937 cells mediated by silencing ATM gene.

Authors:  Jinniu Deng; Jianfeng Zhou; Fankai Meng; Dengju Li; Hanying Sun
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2002

9.  Mouse 24p3 protein has an effect on L929 cell viability.

Authors:  Pei-Tzu Li; Ying-Chu Lee; Namasivayam Elangovan; Sin-Tak Chu
Journal:  Int J Biol Sci       Date:  2007-01-18       Impact factor: 6.580

10.  Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription.

Authors:  V Cepero; B García-Serrelde; V Moneo; F Blanco; A M González-Vadillo; A Alvarez-Valdés; C Navarro-Ranninger; A Carnero
Journal:  Clin Transl Oncol       Date:  2007-08       Impact factor: 3.340

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.